Log In
Print this Print this

Bretaris Genuair, Eklira Genuair, Tudorza Genuair, Tudorza Pressair, aclidinium bromide (Tudorza)

Also known as: LAS34273

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionInhalable long-acting, selective M2 and M3 muscarinic receptor antagonist delivered using the Genuair inhaler
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat bronchospasm associated with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; Treat chronic obstructive pulmonary disease (COPD)
Regulatory Designation Canada - Standard Review (Treat chronic obstructive pulmonary disease (COPD))
PartnerAllergan plc;
Daewoong Pharmaceutical Co. Ltd.;
Kyorin Pharmaceutical Co. Ltd.;
Menarini Group;
Quintiles IMS Holdings Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today